SpringWorks Therapeutics, Inc.

NasdaqGS:SWTX Stock Report

Market Cap: US$4.3b

SpringWorks Therapeutics Management

Management criteria checks 2/4

SpringWorks Therapeutics' CEO is Saqib Islam, appointed in Jul 2018, has a tenure of 6.58 years. total yearly compensation is $18.35M, comprised of 4% salary and 96% bonuses, including company stock and options. directly owns 0.93% of the company’s shares, worth $39.57M. The average tenure of the management team and the board of directors is 4.7 years and 5.5 years respectively.

Key information

Saqib Islam

Chief executive officer

US$18.4m

Total compensation

CEO salary percentage4.0%
CEO tenure6.6yrs
CEO ownership0.9%
Management average tenure4.7yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate

Jan 13

SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great

Dec 31

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Dec 15

Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

Nov 15
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

SpringWorks Therapeutics Merits A Speculative Buy

Nov 04

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Aug 07

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

May 11
Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

May 03
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Apr 25

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Apr 19

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Sep 20
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Jun 07
We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Feb 22
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

SpringWorks drops 21% as Allogene drops lead asset in combination study

Aug 10

SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15

Aug 04

Sizing Up SpringWorks Therapeutics

Jul 20

Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

Jun 06
Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

May 02

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

Dec 30
Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Dec 14

CEO Compensation Analysis

How has Saqib Islam's remuneration changed compared to SpringWorks Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$275m

Jun 30 2024n/an/a

-US$301m

Mar 31 2024n/an/a

-US$339m

Dec 31 2023US$18mUS$725k

-US$325m

Sep 30 2023n/an/a

-US$305m

Jun 30 2023n/an/a

-US$298m

Mar 31 2023n/an/a

-US$289m

Dec 31 2022US$15mUS$680k

-US$277m

Sep 30 2022n/an/a

-US$259m

Jun 30 2022n/an/a

-US$228m

Mar 31 2022n/an/a

-US$206m

Dec 31 2021US$18mUS$590k

-US$174m

Sep 30 2021n/an/a

-US$107m

Jun 30 2021n/an/a

-US$87m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$8mUS$541k

-US$46m

Sep 30 2020n/an/a

-US$73m

Jun 30 2020n/an/a

-US$68m

Mar 31 2020n/an/a

-US$62m

Dec 31 2019US$3mUS$480k

-US$51m

Sep 30 2019n/an/a

-US$41m

Jun 30 2019n/an/a

-US$29m

Mar 31 2019n/an/a

-US$18m

Dec 31 2018US$2mUS$407k

-US$18m

Compensation vs Market: Saqib's total compensation ($USD18.35M) is above average for companies of similar size in the US market ($USD6.60M).

Compensation vs Earnings: Saqib's compensation has increased whilst the company is unprofitable.

CEO

Saqib Islam (54 yo)

6.6yrs

Tenure

US$18,351,489

Compensation

Mr. Saqib Islam, J.D. has been Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isla...

Leadership Team

NamePositionTenureCompensationOwnership
Saqib Islam
CEO & Director6.6yrsUS$18.35m0.93%
$ 39.6m
Francis Perier
Chief Financial Officer5.5yrsUS$3.74m0.038%
$ 1.6m
Badreddin Edris
Chief Operating Officer4.1yrsUS$6.64m0.21%
$ 8.8m
James Cassidy
Chief Medical Officer3.6yrsUS$4.31m0.046%
$ 2.0m
Michael Nofi
Chief Accounting Officer4.9yrsno data0.015%
$ 628.2k
Tai-An Lin
Chief Scientific Officer1.4yrsno data0.0087%
$ 372.4k
Kim Diamond
Vice President of Communications & Investor Relations7.1yrsno datano data
Herschel Weinstein
General Counsel & Secretary5.1yrsUS$2.83m0.030%
$ 1.3m
Daniel Pichl
Chief People Officer4.5yrsUS$2.52m0.021%
$ 917.8k
Bhavesh Ashar
Chief Commercial Officer3.9yrsUS$4.94m0.027%
$ 1.2m

4.7yrs

Average Tenure

56yo

Average Age

Experienced Management: SWTX's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Saqib Islam
CEO & Director6.6yrsUS$18.35m0.93%
$ 39.6m
Alan Fuhrman
Independent Director5.5yrsUS$520.14k0.014%
$ 607.3k
Daniel Lynch
Independent Chairman of the Board9.1yrsUS$545.14k0.41%
$ 17.3m
Martin MacKay
Directorless than a yearno datano data
Freda Lewis-Hall
Independent Director7.5yrsUS$508.45k0.014%
$ 607.3k
Carlos Alban
Independent Director2.6yrsUS$507.64k0.011%
$ 459.5k
Julie Hambleton
Independent Director4.8yrsUS$520.14kno data

5.5yrs

Average Tenure

66yo

Average Age

Experienced Board: SWTX's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 15:32
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SpringWorks Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Alec StranahanBofA Global Research
Cory KasimovEvercore ISI